New antimicrobial agents for methicillin-resistant Staphylococcus aureus.

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


In bacterial and fungal infections, optimal outcomes are obtained through the timely provision of adequate antimicrobial coverage in an initial anti-infective treatment regimen. However, selecting appropriate antimicrobial regimens to treat infections in the intensive care unit is challenging because of the expansion of antibiotic resistance. Multidrug anti-infective regimens are typically needed to adequately cover common important pathogens in ICUs. Here, we describe novel antibacterial agents in the late stages of clinical development that show potential for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These include the fifth-generation cephalosporins, ceftaroline and ceftobiprole; the glycopeptides, dalbavancin, oritavancin, and telavancin; and iclaprim.

Original languageEnglish
Pages (from-to)282-286
Number of pages5
JournalCritical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
Issue number4
StatePublished - Dec 2009


Dive into the research topics of 'New antimicrobial agents for methicillin-resistant Staphylococcus aureus.'. Together they form a unique fingerprint.

Cite this